Physician profile
Ashok Kumar Malani
NPI 1205804903
$3,283.71
in general payments reported to CMS, 2019-2025
40 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.14 · 2020: $151 · 2021: $11.92 · 2022: $16.33 · 2023: $440 · 2024: $1,303 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.55 |
| Education | $260.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $448.87 | 2024-2025 | |
| Janssen Biotech, INC. | $214.90 | 2024-2025 | Erleada, Rybrevant, Tecvayli |
| Pfizer INC. | $197.66 | 2023-2025 | |
| Daiichi Sankyo INC. | $188.87 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $166.67 | 2020-2025 | Keytruda, Keytruda Qlex |
| Genzyme Corporation | $161.21 | 2023-2024 | |
| Puma Biotechnology, INC. | $142.98 | 2023-2025 | Nerlynx |
| Eisai INC. | $141.37 | 2019-2025 | |
| Astellas Pharma US INC | $136.63 | 2023-2025 | Padcev, Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $128.97 | 2020-2025 | Opdivo, Opdualag |
| Karyopharm Therapeutics INC. | $127.96 | 2023-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $127.64 | 2023-2025 | Calquence, Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.83 | 2019-2025 | Gilotrif |
| Gilead Sciences, INC. | $117.55 | 2021-2025 | Trodelvy |
| Sun Pharmaceutical Industries INC. | $81.49 | 2023-2024 | Odomzo, Yonsa |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $68.34 | 2025 | Braftovi, Mektovi, Tukysa |
| Regeneron Healthcare Solutions, INC. | $62.31 | 2024-2025 | Libtayo, Lynozyfic |
| Tempus Ai, INC | $58.44 | 2024-2025 | Xt Cdx |
| Springworks Therapeutics, INC. | $51.41 | 2024-2025 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $49.07 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $45.27 | 2024 | Empaveli |
| Sobi, INC | $43.29 | 2025 | |
| Geron Corporation | $33.87 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $31.70 | 2025 | Talvey, Tecvayli, Darzalex |
| Immunocore Limited | $31.32 | 2024 | Kimmtrak |
| Celgene Corporation | $27.82 | 2024 | Reblozyl |
| Beigene USA, INC. | $27.14 | 2023 | Brukinsa |
| Adc Therapeutics America, INC. | $23.13 | 2023 | |
| Tersera Therapeutics LLC | $22.98 | 2025 | Xermelo |
| Genmab U.S., INC. | $22.68 | 2024 | Epkinly |
| Pharmacosmos Therapeutics INC. | $21.09 | 2025 | Monoferric |
| Taiho Oncology, INC. | $21.06 | 2024 | |
| Pharmaessentia USA Corporation | $20.09 | 2025 | Besremi |
| Stemline Therapeutics INC. | $19.66 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $18.97 | 2025 | Ojjaara |
| Morphosys, US INC. | $16.60 | 2023 | Monjuvi |
| Incyte Corporation | $16.48 | 2024 | Jakafi |
| Lilly USA, LLC | $15.88 | 2019 | |
| Beone Medicines USA, INC. | $15.25 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Malani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.